written on 03.06.2014

Targeted Therapy in NSCLC Part V: KRAS, MEK, BRAF and MET


In the fifth in this series on targeted therapy in non small cell lung cancer (NSCLC), a number of new pathways and potential targets for the future are reviewed. In particular, the mitogen-activated protein kinase (MAPK) pathway, which is preferentially activated in NSCLC. See Part I of the series here. Dependency of BRAF-mutant lung tumours […]